News

Podcast

Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS

Author(s):

Pearl Steinzor

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.

Nathan Walcker

Nathan Walcker

Florida Cancer Specialists & Research Institute's (FCS') Nathan Walcker, CEO, discusses some key strategic practices and initiatives in providing high quality community-based oncology care he has implemented at FCS.

He spoke with us at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event held in Tampa, Florida, on August 10, 2023.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify


Related Videos
Roberto Salgado, MD.
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Screenshot of an interview with Shaun P. McKenzie, MD
Hans Lee, MD
Don M. Benson, MD, PhD, James Cancer Hospital
Screenshot of Jennifer Vaughn, MD, during a Zoom interview
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Related Content
AJMC Q&A with Ian Neeland, MD | Background image credit: ipopba - stock.adobe.com
December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

Hayden E. Klein
Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
NSCLC Thumbnail
December 20th 2024

Top 5 NSCLC Content for 2024

Maggie L. Shaw
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.
Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF
December 12th 2024

Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF

A trio of experts discuss the importance of early diagnosis, treatment barriers, and therapies in the pipeline for idiopathic pulmonary fibrosis (IPF).
Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.
chemotherapy | Image credit: Penn Medicine
December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo